Int J Pharm Bio Sci 2014 July ; 5 (3) : (P) 526 - 532

Research Article **Medicinal chemistry**

International Journal of Pharma and Bio Sciences **ISSN 0975-6299**

NEW SUBSTITUTED C(14)-ANDROGRAPHOLIDE DERIVATIVES WITH POTENT CYTOTOXIC ACTIVITIES

RAVINDRA PATIL*, VENKAT R. P AND VIROHIT PATIL.

Department of Pharmaceutical Sciences, Allana College of Pharmacy, Pune, Maharashtra, India, 411038.

ABSTRACT

Andrographolde is the major secondary metabolite from the plant *Andrographis* paniculata. It has been found to show cytotoxic activity. To improve the efficacy on cytotoxic activity, a series of new sulfonyl derivatives have been synthesized by structural modifications of the andrographolide at C-2 position. All the derivatives were tested for their cytotoxic activity against human small lung cancer (NCI-H187), leukemia K562, breast cancer (MCF-7/ADR) and lung adenocarcinoma (A549) cell lines. Most of the compounds have appreciable activity at tested cell lines. Compound 4a exhibited higher cytotoxic activity than parent compound andrographolide.

KEY WORDS: Andrographis *paniculata,* Andrographolide, cytotoxic activity, sulfonyl type of analogues.

RAVINDRA PATIL
Department of Pharmaceutical Sciences, Allana College of Pharmacy,
Pune, Maharashtra, India, 411038.

INTRODUCTION

Andrographolide (1) is isolated from the whole plant of *Andrographis paniculata* (family Acanthaceae), is extensively used in the traditional system of medicine in south east Asia since antiquity.[1] Extracts of plants and their constituents including andrographolide (1) have been reported to exhibit a wide range of biological activities [2-18] of therapeutic importance that include anti-inflammatory, hepatoprotective, antimalarial, antibacterial, antithrombotic, immune stimulant, antidepressive, antiallergic, central nervous system disorders, anti HIV, and anticancer[19]. Since its discovery of plethora of activities, a large number of andrographolide (1) derivatives have been prepared by semi-synthesis for the modification of the biological activities which are available in the literature.[19-28] Presuming that incorporation of sulfonyl esters at C-14 in andrographolide might generate some bioactive molecules, herein, we report the synthesis of a new series of sulfonyl ester andrographolide derivatives and their cytotoxic activity against human small lung cancer (NCI-H187), leukemia K562, breast cancer (MCF-7/ADR) and lung adenocarcinoma (A549) cell lines.

MATERIALS AND METHODS

Whole plant of *Andrographis paniculata* was collected from botanical herbarium (Herbarium no. Bot/117A); Orissa, India in the months of March 2013. Reagents and chemicals were purchased from sigma-aldrich, and 2-chloro phenyl sulfonyl chloride was purchased from Invocon pharmaceuticals, Maharashtra.

RESULTS AND DISCUSSION

Andrographolide (1) was isolated in high yields from the plant of *Andrographis paniculata* and used as the starting material for the preparation of the C(14)-modified sulfonyl analogue library 4a-4g (Scheme 1). Initially, Andrographolide 1 was treated with 2, 2-dimethoxy propane in the presence of pyridinium *p*-toulenesulfonate (PPTS) in CH_2Cl_2 at 40^oC to yield 87% of compound 2. Compound 2 was treated with appropriate sulfonyl halides in the presence of diisopropylethyl amine base in DCM to give compounds 3a-3g. Derivatives 4a-4g were prepared in yields of 69-73% by reacting compounds 3a-3g with acetic acid in water to remove isopropylidene (Scheme 1).



Scheme 1

Synthesis of sulfonylester-type andrographolide analogs 4a-4i. Reagents and conditions: (a) 2,2-dimethoxypropane, PPTS, DCM, reflux at 40°C, 1h; (b) appropriate sulfonyl chloride, Et_3N, dry DCM, N_2, r.t, 3-4 h; (c) Acetic acid, H_2O, r.t, 30 min.

BIOLOGICAL ACTIVITY

Andrographolide (1) and its sulfonyl ester type analogs (4a-4g) were evaluated for their *in vitro* cytotoxic activity against human small lung cancer (NCI-H187), leukemia K562, breast cancer (MCF-7/ADR) and lung adenocarcinoma (A549) cell lines. The *in vitro* cytotoxic activity assays were conducted using classical MTT method.[29] The cytotoxicity data of 1 and its analogs are collated in Table 1. For comparison purpose, IC_{50} values of positive control, cisplatin against cell lines are included in the Table 1. Most of the synthesized sulfonyl ester derivatives showed appreciable cytotoxic activity compared to the parent compound Andrographolide 1 against tested cell lines. Analogs 4a and 4b have also shown potent activity than the standard cisplatin and parent compound Andrographolide 1.

Table 1
Cytotoxicity effects of C(14)-sulfonyl ester-derived andrographolide analogues (4a-4g) against cancer cell lines

Cell lines (IC_{50} µM)[a]				
Compound	**NCI-H187**	**K562**	**MCF-7/ADR**	**A549**
1	7.85±3.50	16.18±3.35	13.82±2.56	4.17±1.15
4a	6.24±1.65[b]	5.97±2.20	11.30±3.45	3.98±1.63
4b	10.83±2.17	12.98±1.85	15.63±3.64	7.50±2.19
4c	>130	76.55±12.75	>165	NT
4d	11.15±2.30	13.90±2.55	22.85±5.45	7.96±1.85
4e	16.20±4.30	15.76±5.36	29.74±4.94	8.95±2.73
4f	29.56±6.85	33.85±7.50	23.80±6.50	11.85±3.20
4g	44.85±7.85	51.18±8.80	36.54±5.45	17.65±4.60
Cisplatin[c]	2.79±0.50	3.76±0.85	9.55±1.25	0.86±0.35

[a] Concentration of compound required to inhibit cell growth by 50% as determined by MTT assay; [b]data are expressed as mean±standard deviation; [c]Cisplatin was used as positive control; NA- not active; NT- not tested;

As demonstrated in table 1, among all derivatives methyl sulfony derivative 4a and ethyl sulfony analog 4b have significant cytotoxic activity against tested cell lines. The methyl sulfonyl derivative 4a had higher activity than parent compound andrographolide 1 (IC_{50}= 6.26 *vs* 17.85 µM against NCI-H187; 5.97 *vs* 16.18 µM against K562; 11.30 *vs* 13.82 µM against MCF-7; 3.98 *vs* 4.17 µM against A549 respectively), and reduced activity than standard drug cisplatin against tested cell lines (IC_{50}= 6.24 *vs* 2.79 µM against NCI-H187; 5.97 *vs* 3.76 µM against K562; 11.30 *vs* 9.55 µM against MCF-7; 3.98 *vs* 0.86 µM against A549 respectively) (Table 1). The ethyl sulfony derivative 4b had higher activity than 1 against NCI-H187 and K562 cell lines (IC_{50}= 10.83 *vs* 17.85 µM; 12.98 *vs* 16.18 µM respectively) (Table 1), and reduced activity than cisplatin. Similarly, the vinyl sulfonyl derivative 4d had higher activity than 1 against NCI-H187 and K562 cell lines (IC_{50}= 11.15 *vs* 17.85 µM; 13.90 *vs* 16.18 µM respectively); and also trifluoromethyl sulfony derivative 4e had higher activity than 1 against NCI-H187 and K562 cell lines (IC_{50}= 16.20 *vs* 17.85 µM; 15.76 *vs* 16.18 µM respectively) (Table 1). Compounds 4f and 4g have reduced activity than standard cisplatin, but still show appreciable activity compared to the parent andrographolide 1 (Table 1); this reducing activity against cell lines may be due to the presence of bulkier aromatic ring in their structures at C-14 position. Analog 4c had no activity against tested cell lines; presence of chloro group may reduce the cytotoxic activity.

CONCLUSION

In summary, a series of new sulfonyl ester-type analogs of andrographolide were synthesized in an effort to explore the cytotoxic effects of C-14 substitution against human small lung cancer (NCI-H187), leukemia K562, breast cancer (MCF-7/ADR) and lung adenocarcinoma (A549) cell lines. Most of the analogs showed significant cytotoxic activity against tested cell lines compared to the parent andrographolide. Analogs methyl sulfonyl derivative 4a and ethyl sulfonyl derivative 4b have higher activity than parent compound andrographolide against NCI-H187, K562 and MCF-7 cell lines.

ACKNOWLEDGEMENT

The authors are thankful to Head of the department of Pharmaceutical sciences, Allana College of Pharmacy. We also thankful to Invocan Pharmaceuticals, Aurangabad, Maharashtra for providing NMR and mass data for synthesized compounds, and also to Rubicon formulations for biological activity studies.

^{1}H-NMR, ^{13}C-NMR AND MS DATA FOR ALL DERIVATIVES

Methylsulfonyl-14-*O*-andrographolide (4a). White amorphous powder, ^{1}H NMR (400 MHz, CDC_{l3}): δ 7.04 (t, *J* = 6.8 Hz, 1H), 5.98 (d, *J* = 5.8 Hz, 1H), 4.91 (s, 1H), 4.57-4.51 (m, 2H), 4.24-4.15 (m, 2H), 3.91 (d, *J* = 11.6 Hz, 1H), 3.71(s, 3H), 3.51-3.48 (m, 1H), 3.31 (d, *J* = 10.6 Hz, 1H), 3.19 (s, 2H), 2.51-2.31 (m, 4H), 1.99-1.94 (m, 1H), 1.80-1.71 (m, 5H), 1.32-1.15 (m, 6H), 0.69 (s, 3H). ^{13}C NMR (100 MHz, CDC_{l3}): δ 174.9, 168.6, 165.1, 152.2, 148.6, 124.2, 109.1, 80.9, 72.6, 70.3, 63.9, 62.1, 57.2, 55.9, 52.6, 43.9, 39.9, 38.2, 37.2, 29.4, 26.3, 25.7, 23.4, 16.1. HRESIMS *(m/z)*: $[M+H]^+$ calculated for $C_{21}H_{32}O_7S$, 429.1941; found, 429.1936.

Ethylsulfonyl-14-*O*-andrographolide (4b). White amorphous powder, ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.03 (t, *J* = 6.8 Hz, 1H), 5.99 (d, *J* = 5.8 Hz, 1H), 4.90 (s, 1H), 4.57-4.52 (m, 2H), 4.26-4.11 (m, 4H), 3.92 (d, *J* = 11.6 Hz, 1H), 3.51-3.46 (m, 1H), 3.32 (d, *J* = 10.6 Hz, 1H), 3.19 (s, 2H), 2.51-2.31 (m, 4H), 1.99-1.94 (m, 1H), 1.79-1.71 (m, 5H), 1.34-1.12 (m, 9H), 0.71 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 175.1, 169.7, 165.3, 152.9, 148.7, 124.5, 109.2, 80.8, 72.8, 70.4, 63.7, 61.3, 58.2, 55.7, 52.3, 43.8, 39.8, 38.1, 37.3, 29.5, 26.4, 25.3, 23.8, 14.6, 16.4. HRESIMS (*m/z*): $[M+H]^+$ calculated for $C_{22}H_{34}O_7S$, 443.2154; found, 443.2143.

Chloromethylsulfonyl 14-*O*-andrographolide (4c). White amorphous powder, ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.03 (t, *J* = 6.8 Hz, 1H), 5.96 (d, *J* = 5.8 Hz, 1H), 4.90 (s, 1H), 4.57-4.52 (m, 2H), 4.26-4.11 (m, 4H), 3.92 (d, *J* = 11.6 Hz, 1H), 3.51-3.46 (m, 1H), 3.32 (d, *J* = 10.6 Hz, 1H), 3.21 (s, 3H), 2.51-2.31 (m, 4H), 1.99-1.94 (m, 1H), 1.79-1.71 (m, 5H), 1.36 (s, 9H), 1.34-1.12 (m, 9H), 0.71 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 174.8, 169.3, 164.9, 152.2, 148.1, 124.4, 109.1, 82.3, 80.8, 72.9, 70.6, 63.6, 58.1, 55.6, 52.3, 43.8, 39.9, 38.2, 37.4, 28.9 (3×*t*-$\underline{C}H_3$), 29.4, 26.4, 25.3, 23.6, 16.8. HRESIMS (*m/z*): $[M+H]^+$ calculated for $C_{21}H_{31}ClO_7S$, 464.1419; found, 464.1403.

Vinylsulfonyl 14-*O*-andrographolide (4d). White amorphous powder, ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.03 (t, *J* = 6.8 Hz, 1H), 5.96 (d, *J* = 5.8 Hz, 1H), 4.90 (s, 1H), 4.57-4.52 (m, 2H), 4.26-4.11 (m, 4H), 3.92 (d, *J* = 11.6 Hz, 1H), 3.67 (s, 3H), 3.51-3.46 (m, 1H), 3.32 (d, *J* = 10.6 Hz, 1H), 2.84-2.69 (m, 4H), 2.51-2.31 (m, 4H), 1.99-1.94 (m, 1H), 1.79-1.71 (m, 5H), 1.36 (s, 9H), 1.34-1.12 (m, 9H), 0.71 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 175.1, 169.1, 165.3, 151.9, 148.9, 123.3, 108.9, 80.7, 72.5, 70.2, 63.8, 62.2, 57.3, 55.8, 51.8, 43.8, 39.8, 38.2, 37.1, 29.5, 29.2, 26.4, 25.4, 23.6, 16.3. HRESIMS (*m/z*): $[M+H]^+$ calculated for $C_{22}H_{32}O_7S$, 441.1913; found, 441.1904.

Triflоromethylsulfonyl-14-*O*-andrographolide (4e). White amorphous powder, ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.03 (t, *J* = 6.8 Hz, 1H), 5.96 (d, *J* = 5.8 Hz, 1H), 4.90 (s, 1H), 4.57-4.52 (m, 2H), 4.26-4.09 (m, 6H), 3.92 (d, *J* = 11.6 Hz, 1H), 3.67 (s, 3H), 3.51-3.46 (m, 1H), 3.32 (d, *J* = 10.6 Hz, 1H), 2.83-2.68 (m, 4H), 2.51-2.31 (m, 4H), 1.99-1.94 (m, 1H), 1.79-1.71 (m, 5H), 1.29 (t, 3H), 1.34-1.12 (m, 9H), 0.71 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 175.1, 169.1, 165.3, 151.9, 148.9, 123.3, 108.9, 80.7, 72.5, 70.2, 63.8, 61.7, 62.2, 57.3, 55.8, 43.8, 39.8, 38.2, 37.1, 29.6, 29.4, 26.4, 25.4, 23.6, 16.3, 14.1. HRESIMS (*m/z*): $[M+H]^+$ calculated for $C_{21}H_{29}F_3O_7S$, 483.1612; found, 483.1608.

Phenylsulfonyl 14-*O*-andrographolide (4f). White amorphous powder, ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.73-7.42 (m, 5H), 7.03 (t, *J* = 6.8 Hz, 1H), 5.96 (d, *J* = 5.8 Hz, 1H), 4.90 (s, 1H), 4.57-4.52 (m, 2H), 4.26-4.09 (m, 6H), 3.92 (d, *J* = 11.6 Hz, 1H), 3.63 (s, 3H), 3.51-3.46 (m, 1H), 3.32 (d, *J* = 10.6 Hz, 1H), 2.83-2.68 (m, 4H), 2.55-2.29 (m, 10H), 1.99-1.94 (m, 1H), 1.79-1.71 (m, 5H), 1.29 (t, 3H), 1.34-1.12 (m, 9H), 0.71 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 175.1, 171.1, 168.3, 151.9, 148.9, 134.5, 128.3, 123.3, 108.9, 80.7, 72.5, 70.2, 63.8, 62.2, 57.3, 55.8, 51.9, 43.8, 39.8, 38.2, 37.1, 29.5, 29.2, 26.4, 25.4, 33.9, 33.4, 20.1, 16.3. HRESIMS (*m/z*): $[M+H]^+$ calculated for $C_{26}H_{34}O_7S$, 491.2132; found, 491.2127.

Ortho-phenylsulfonyl 14-*O*-andrographolide -14-*O*-adipate (4g). White amorphous powder, ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.79-7.46 (m, 4H), 7.02 (t, *J* = 6.8 Hz, 1H), 5.97 (d, *J* = 5.8 Hz, 1H), 4.90 (s, 1H), 4.57-4.52 (m, 2H), 4.26-4.09 (m, 6H), 3.92 (d, *J* = 11.6 Hz, 1H), 3.64 (s, 3H), 3.51-3.46 (m, 1H), 3.32 (d, *J* = 10.6 Hz, 1H), 2.83-2.68 (m, 4H), 2.55-2.29 (m, 10H), 1.99-1.94 (m, 1H), 1.79-1.71 (m, 5H), 1.65-1.61 (m, 4H), 1.29 (t, 3H), 1.34-1.12 (m, 9H), 0.71 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 175.1, 171.1, 168.3, 151.9, 148.9, 128.1, 126.1, 123.3, 108.9, 80.7, 72.5, 70.2, 61.9, 62.2, 57.3, 55.8,

43.8, 39.8, 38.2, 37.1, 29.5, 29.2, 26.4, 25.4, 34.4, 34.1, 24.3, 24.1, 16.3. HRESIMS (*m/z*): $[M+H]^+$ calculated for $C_{26}H_{33}ClO_7S$, 526.1645; found, 526.1639.

REFERENCES

1. Chakravarti RN, Chakravarti D, Andrographolide, The Active Constituent of *Andrographis paniculata* Nees; A Preliminary Communication, Ind. Med. Gaz. 86:96-97, (1951).
2. Shen YC, Chen CF, Chiou WF, Andrographolide Prevents Oxygen Radical Production by Human Neutrophils: Possible Mechanism(s) Involved in its Anti-Inflammatory Effect, Br. J. Pharmacol, 135: 399-406, (2002).
3. Najib Nik ARN, Furuta T, Kojima S, Takane K, Ali MM, Antimalarial Activity of Extracts of Malaysian Medicinal Plants, J. Ethanopharmacol., 64: 249-254, (1999).
4. Gupta S, Choudary MA, Yadava JNS, Srivastava V, Tandon JS, Antidiarrhoeal Activity of Diterpenes of *Andrographis paniculata* (Kal-Megh) against *Escherichia coli* Enterotoxin in *in vivo* Models, Pharmaceutical Biology, 28: 273-283, (1990).
5. Gupta PP, Tandon JS, Patnaik GK, Antiallergic Activity of Andrographolides Isolated from *Andrographis paniculata* (Burm. F) Wall, Pharmaceutical Biology, 1998, 36: 72-74, (1998).
6. Madav S, Tanda SK, Lal J, Tripatthi HC, Anti-inflammatory Activity of Andrographolide. Fitoterapia, 67: 452-458, (1996).
7. White KL, Scopton AP, Rives ML, Bikulatov RV, Polepally PR, Brown PJ, Kenakin T, Javitch JA, Zjawiony JK, Roth BL, Identification of Novel Functionally Selective κ-Opioid Receptor Scaffolds. *Mol. Pharmacol.* 85: 83-90, (2014).
8. Husen R, Pihie AHL, Nallappan M, Screening for Antihyperglycaemic Activity in Several Local Herbs of Malaysia, J. Ethnopharmacol. 95: 205-208, (2004).
9. Polepally PR, White K, Vardy E, Roth BL, Ferreira D, Zjawiony JK, Kappa-Opioid Receptor-Selective Dicarboxylic Ester-Derived Salvinorin A Ligands. Bioorg. Med. Chem. Lett., 23**:** 2860-2862, (2013).
10. Handa SS, Sharma A, Hepatoprotective Activity of Andrographolide from *Andrographis paniculata* Against Galactosamine and Paracetamol-induced toxicity Indian J. Med. Res. 92: 284-292, (1990).
11. Shen YC, Chen CF, Chiou WF, Suppression of Rat Neutrophil Reactive Oxygen Species Production and Adhesion by the Diterpenoid Lactone Andrographolide, Planta Med. 66: 314-317, (2000).
12. Li Z, Huang W, Zhang H, Wang X, Zhou H, Synthesis of Andrographolide Derivatives and their TNF-α and IL-6 Expression Inhibitory Activities, Bioorg. Med.Chem. Lett. 17**:** 6891-6894, (2007).
13. Zjawiony JK, Polepally PR, Roth BL, Setola V, Vardy E, Design and Synthesis of Natural-Product Based Ligands with High Affinity to the Kappa-Opioid Receptor, Planta Med. 77(12): SL4, (2011).
14. Kumar RA, Sridevi K, Kumar NV, Nanduri S, Srinivas N, Rajagopal SJ, Anticancer and Immunostimulatory Compounds from *Andrographis paniculata*., J. Ethnopharmacol. 92: 291-295, (2004).
15. Polepally PR, Setola V, Vardy E, Roth BL, Mosier PD, Zjawiony JK, New Salvinorin A-Derived Ligands to Opioid Receptors. Planta Med. 78**:** PI238, (2012).
16. Reddy PP, Raju BC, Rao JM, A Facile One-Pot Friedlander Synthesis of Quinoline Derivatives, J. Chem. Res*.* 12: 679-682, (2008).
17. Polepally PR, Setola V, Vardy E, Roth BL, Zjawiony JK, Convenient Synthesis And *In Vitro* Pharmacological Activity of Thioesters of Salvinorin B, Planta Med. *79*(05)*,* P43, (2013).
18. Raju BC, Pradeep DVS, Reddy PP, Rao JM, CBr_4 Catalyzed Synthesis of Aryl-14H-

dibenzo [a,j] Xanthenes Under Solvent-Free Conditions, Lett. in Org. Chem. 5: 450-454, (2008).

19. Srinivasan RG, Lakshmana B, Anjinayulu D. Kumar, Shalem Raju K, Halem Raju. "Naturevolution Effective Against Cancer Therapy-Review (Treating Cancer Diseases Using Plant Products), *International Journal of Pharma & Bio Sciences* 5(2): 357-365, (2014).
20. Polepally PR, Setola V, Vardy E, Roth BL, Zjawiony JK, New Michael Acceptor-Type of Salvinorin A Ligands to Kappa-Opioid Receptor, Planta Med. 79(05): P41, (2013).
21. Nanduri S, Nyavanandi VK, Thunuguntla SSR, Kasu S, Pallerla MK. *et al* Synthesis and Structure-Activity Relationships of Andrographolide Analogues as Novel Cytotoxic Agents, Bioorg. Med. Chem. Lett. 14: 4711-4717, (2004).
22. Polepally PR, Roth BL, White K, Ferriera D, Zjawiony JK, Synthesis and *In vitro* Biological Evaluation of New Dicarboxylic Ester-Type Salvinorin A Analogs, Planta Med. 79(05): P42, (2013).
23. He XJ, Li JK, Gao H, Qiu F, Hu K, Cui XM, Yao XS, Four New Andrographolide Metabolites in Rats, Tetrahedron Lett. 59: 6603-6607, (2003).
24. Polepally PR, Roth BL, White K, Zjawiony JK, Synthesis and Biological Evaluation of New Salvinorin B-Sulfonate Ester Ligands to Opioid Receptors. Planta Med.79(05): P44, (2013).
25. Polepally PR, White K, Roth BL, Zjawiony JK, Synthesis and *In Vitro* Pharmacological Activity of C-2 Modified New Salvinorin A Analogues. Planta Med. 79(05): P45, (2013).
26. Li Z, Huang W, Zhang H, Wang X, Zhou H, Synthesis of Andrographolide Derivatives and their TNF-α and IL-6 Expression Inhibitory Activities, Bioorg. Med. Chem. Lett. 16**,** 6891-6894, (2007).
27. Fajemiroye OJ, Galdino PM, Florentino IF, DaRocha FF, Ghedini PC, Polepally PR, Zjawiony JK, Costa EA, Oleanolic acid: Plurality of anxiety and depression alteration mechanism by oleanolic acid, Journal of Psychopharmacology, (2014), doi:10.1177/0269881114536789, in press.
28. Salaga M, Prabhakar RP, Sobczak DG, Sibaev A, storr M, Dorego JC, Jordan KZ**,** Jakub JF, (2014). Novel orally available salvinorin A Analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse Models mimicking irritable bowel syndrome. J. Pharmaceutical. Exper. Therapeutics, 85: 83-90, (2014).
29. Anne M, Dominic S, Philip S, Robert S, Kenneth P, David V, Curtis H, John L, Paul C, Anne V, Marcia G, Hugh C, Joseph M, Michael B, Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines*, J. Nat. Cancer Inst.,* 83: 757-766, (1991).